Esperion Therapeutics, Inc.
ESPR
$1.50
$0.000.00%
| Weiss Ratings | ESPR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ESPR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ESPR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.79 | |||
| Price History | ESPR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -9.09% | |||
| 30-Day Total Return | -17.13% | |||
| 60-Day Total Return | -33.33% | |||
| 90-Day Total Return | -26.47% | |||
| Year to Date Total Return | -31.82% | |||
| 1-Year Total Return | -26.83% | |||
| 2-Year Total Return | -62.69% | |||
| 3-Year Total Return | -68.35% | |||
| 5-Year Total Return | -94.53% | |||
| 52-Week High % Change | -61.93% | |||
| 52-Week Low % Change | 2.04% | |||
| Price | ESPR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $3.94 | |||
| 52-Week Low Price | $1.47 | |||
| 52-Week Low Price (Date) | Mar 13, 2025 | |||
| 52-Week High Price (Date) | Dec 09, 2024 | |||
| Valuation | ESPR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 296.77M | |||
| Enterprise Value | 743.22M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.25 | |||
| Earnings Per Share Growth | -88.06% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.88 | |||
| Price/Book (Q) | -0.76 | |||
| Enterprise Value/Revenue (TTM) | 2.24 | |||
| Price | $1.50 | |||
| Enterprise Value/EBITDA (TTM) | 13.64 | |||
| Enterprise Value/EBIT | 13.66 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | ESPR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 195.57M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ESPR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 734 887 3903 | |||
| Address | 3891 Ranchero Drive Ann Arbor, MI 48108 | |||
| Website | www.esperion.com | |||
| Country | United States | |||
| Year Founded | 2008 | |||
| Profitability | ESPR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 16.37% | |||
| Profit Margin | -15.57% | |||
| Management Effectiveness | ESPR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 12.37% | |||
| Return on Equity | -- | |||
| Income Statement | ESPR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 332.31M | |||
| Total Revenue (TTM) | 332.31M | |||
| Revenue Per Share | $1.70 | |||
| Gross Profit (TTM) | 217.48M | |||
| EBITDA (TTM) | 54.50M | |||
| EBIT (TTM) | 54.40M | |||
| Net Income (TTM) | -51.75M | |||
| Net Income Avl. to Common (TTM) | -51.75M | |||
| Total Revenue Growth (Q YOY) | 114.30% | |||
| Earnings Growth (Q YOY) | 62.16% | |||
| EPS Diluted (TTM) | -0.25 | |||
| EPS Diluted Growth (Q YOY) | 78.26% | |||
| Balance Sheet | ESPR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 144.76M | |||
| Cash Per Share (Q) | $0.74 | |||
| Total Current Assets (Q) | 338.00M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -388.72M | |||
| Current Ratio (Q) | 1.373 | |||
| Book Value Per Share (Q) | -$1.98 | |||
| Total Assets (Q) | 343.82M | |||
| Total Current Liabilities (Q) | 246.23M | |||
| Total Debt (Q) | 591.21M | |||
| Total Liabilities (Q) | 732.54M | |||
| Total Common Equity (Q) | -388.72M | |||
| Cash Flow | ESPR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -317.00K | |||
| Cash from Financing (TTM) | 86.48M | |||
| Net Change in Cash (TTM) | 62.51M | |||
| Levered Free Cash Flow (TTM) | -43.47M | |||
| Cash from Operations (TTM) | -23.65M | |||
